LIXTE Biotechnology shares surge 21.79% after-hours after acquiring Liora's LiGHT proton therapy system.

Lixte Biotechnology Holdings (NASDAQ:LIXT) surged 21.79% in after-hours trading following the announcement of its acquisition of Liora Technologies, a pioneer in proton therapy systems. The deal grants Lixte ownership of Liora’s proprietary LiGHT System, which delivers high-dose proton therapy to deep-seated tumors with reduced treatment sessions and installation costs compared to existing technologies. The system’s potential to enhance treatment efficiency and capacity, coupled with endorsements from experts like former CERN director Professor Steve Myers, positions the acquisition as a strategic expansion into advanced cancer therapies. This move aligns with Lixte’s focus on innovating cancer treatments and strengthens its pipeline, likely driving the significant after-hours price increase.